Epidermal growth factor receptor mutation and pattern of brain metastasis in patients with non-small cell lung cancer
| Autor: | Eun Kyung Cho, Shin Myung Kang, Jae Hoon Lee, Sun Jin Sym, Junshik Hong, Dong Bok Shin, Young Saing Kim, Inkeun Park, Jinny Park, Kyu Ree Park, Hee Kyung Ahn, Min Young Baek, Hwa Sun Park |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2016 |
| Předmět: |
0301 basic medicine
Oncology Adult Male medicine.medical_specialty Lung Neoplasms 03 medical and health sciences Hemato-Oncology 0302 clinical medicine Epidermal growth factor Statistical significance Internal medicine Carcinoma Medicine Humans Epidermal growth factor receptor Receptor Lung cancer Aged Retrospective Studies Aged 80 and over biology business.industry Brain Neoplasms Wild type Receptor epidermal growth factor Brain metastases Carcinoma non-small-cell lung Middle Aged medicine.disease Prognosis ErbB Receptors 030104 developmental biology 030220 oncology & carcinogenesis Mutation biology.protein Original Article Female business Brain metastasis |
| Zdroj: | The Korean Journal of Internal Medicine |
| ISSN: | 2005-6648 1226-3303 |
| Popis: | BACKGROUND/AIMS We investigated the time taken for patients with metastatic non-small cell lung cancer (NSCLC) to develop brain metastases (BM), as well as their subsequent overall median survival following diagnosis, considering the epidermal growth factor receptor (EGFR) mutational status. METHODS We retrospectively investigated the medical records of 259 patients diagnosed with advanced NSCLC from January 2010 to August 2013, who were tested for EGFR mutations. The time from the diagnosis of advanced NSCLC to the development of BM and the overall median survival after BM development (BM-OS) were evaluated and compared by EGFR mutational status. RESULTS Sixty-seven patients (25.9%) developed BM. Synchronous BM occurred more often in patients with EGFR mutation type (MT) (n = 20, 27.4%) compared with EGFR wild type (WT) (n = 27, 14.5%, p < 0.009). The median BM-OS was significantly longer in patients with EGFR MT than in those with EGFR WT (25.7 months vs. 3.8 months, p < 0.001), and a similar trend was noticed for patients with synchronous BM (25.7 months for EGFR MT vs. 6.8 months for EGFR WT, p < 0.001). However, in patients with metachronous BM development, the difference in BM-OS between patients with EGFR MT (14.6 months) and EGFR WT (2.5 months) did not reach statistical significance (p = 0.230). CONCLUSIONS Synchronous BM was more common in NSCLC patients with EGFR MT than in those with EGFR WT. However, EGFR mutations were associated with significantly longer median BM-OS, especially when the brain was the first metastatic site. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|